Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | POLB | P06746 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 4/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18740218 | 0.94 | MEN1 (0.44) | MEN1KMT2AMAPTPOLBTP53 | |
| SCHEMBL18740168 | 0.92 | KDM4E (0.41) | MEN1KMT2APOLBCYP1A2SMN1; SMN2 | |
| SCHEMBL18758571 | 0.90 | PKM (0.41) | MEN1KMT2AMAPTCYP1A2CYP2C9 | |
| SCHEMBL18739995 | 0.87 | GRIA2 (0.40) | MAPTPOLBTP53CYP1A2GRIA2 | |
| SCHEMBL18740240 | 0.86 | MEN1 (0.45) | MEN1KMT2AMAPTCYP1A2CYP2C9 | |
| SCHEMBL18739965 | 0.85 | MEN1 (0.44) | MEN1KMT2ACYP1A2SMN1; SMN2ALDH1A1 | |
| SCHEMBL18740289 | 0.85 | MEN1 (0.44) | MEN1KMT2AMAPTCYP1A2SMN1; SMN2 | |
| SCHEMBL18740201 | 0.85 | MEN1 (0.54) | MEN1KMT2AMAPTPOLBTP53 | |
| SCHEMBL18758706 | 0.85 | ALDH1A1 (0.42) | MEN1KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL18740196 | 0.85 | KMT2A (0.44) | MEN1KMT2AMAPTPOLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11434246-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-09-06 | — | — | US | disclosed |
| EP-3362454-B1 | EP4 ANTAGONISTS | EISAI R&D MAN CO LTD (JP) | 2021-12-08 | — | — | EP | disclosed |
| US-20210347779-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-11-11 | — | — | US | disclosed |
| US-20210347779-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-11-11 | — | — | US | disclosed |
| CN-108473497-B | EP4 antagonists | 卫材R&D 管理有限公司 | 2021-09-10 | — | — | CN | disclosed |
| US-10941148-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-03-09 | — | — | US | disclosed |
| US-10941148-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-03-09 | — | — | US | disclosed |
| US-20190315754-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-10-17 | — | — | US | disclosed |
| US-20190315754-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-10-17 | — | — | US | disclosed |
| US-10316040-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-06-11 | — | — | US | disclosed |
| US-10316040-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-06-11 | — | — | US | disclosed |
| US-20180305362-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-10-25 | — | — | US | disclosed |
| EP-3362454-A1 | EP4 ANTAGONISTS | Eisai R&D Management Co., Ltd. (JP) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017066633-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066633-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11434246-B2 | EP4 antagonists | PTGER4, PTGER3, PTGER1 | MEN1 1667/4885KMT2A 3284/4885MAPT 4565/4885 |
| US-20180305362-A1 | EP4 ANTAGONISTS | PTGER4, PTGER3, PTGER1 | MEN1 1667/4885KMT2A 3284/4885MAPT 4565/4885 |
| US-10316040-B2 | EP4 antagonists | PTGER4, PTGER3, PTGER1 | MEN1 1667/4885KMT2A 3284/4885MAPT 4565/4885 |
| US-10941148-B2 | EP4 antagonists | PTGER4, PTGER3, PTGER1 | MEN1 1667/4885KMT2A 3284/4885MAPT 4565/4885 |
| US-20190315754-A1 | EP4 ANTAGONISTS | PTGER4, PTGER3, PTGER1 | MEN1 1667/4885KMT2A 3284/4885MAPT 4565/4885 |
| US-20210347779-A1 | EP4 ANTAGONISTS | PTGER4, PTGER3, PTGER1 | MEN1 1667/4885KMT2A 3284/4885MAPT 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.